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Abstract: The human gut microbiota is a complex ecosystem and has an essential role in maintaining
intestinal and systemic health. Microbiota dysbiosis is associated with a number of intestinal and
systemic conditions and its modulation for human health is of great interest. Gut microbiota is a
source of novel health-promoting bacteria, often termed as next-generation probiotics in order to
distinguish them from traditional probiotics. The previous lessons learned with traditional probiotics
can help the development of next-generation probiotics that target specific health issues and needs.
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Human intestinal microbiota is a highly diverse population of microbes consisting of bacteria,
archaea, fungi, viruses, and protozoa, and it is considered to have a major contribution to human
health [1]. Microbiota alterations in the composition, diversity, and temporal stability (microbiota
dysbiosis) have been associated with a number of gastrointestinal (GI) and systemic conditions [1].
Therefore, modulation of the intestinal microbiota to maintain a favorable balance in the ecosystem
and to improve human health is of great interest.
The review “Effects of Probiotics, Prebiotics, and Synbiotics on Human Health” [2] summarizes
the evidence and discusses the possibilities of influencing gut and systemic health with nutritional
approaches using probiotics, prebiotics, and their combinations (synbiotics). Probiotics are defined as
“live strains of strictly selected microorganisms that, when administered in adequate amounts, confer a
health benefit on the host”. The most commonly used probiotic strains belong to the genera Lactobacillus
and Bifidobacterium, but also Lactococcus, Streptococcus, Enterococcus, and Bacillus spp. and some yeast
strains belonging to the genus Saccharomyces have been included in probiotic products for human
nutrition [2]. The use of probiotics in food products is based on their safety records for human use, and
most of the used species have Generally Regarded as Safe (GRAS; FDA, US) or Qualified Presumption
of Safety (QPS; EFSA, EU) status [2]. Prebiotics are defined as nonviable food components that confer
a health benefit on the host which is associated with modulation of the microbiota. Nondigestible
oligosaccharides such as fructo- and galactooligosaccharides and inulin (a fructopolysaccharide) are
among the most studied prebiotics [2].
Based on the extensive summary of probiotic clinical trials by Markowiak and S´liz˙ewska [2],
it seems that probiotics have clinical benefits especially in populations that are at risk of developing a
disease, but more clinical investigations should be done to verify the efficacy. The authors underline
that the effects may depend on the strain, dose, and components used to produce a given probiotic
product [2]. Endogenous microbiota adds yet another factor that can have an impact on the probiotic
efficacy at the individual level, as it may impact colonization and functionality of the administered
strain. In general, orally consumed probiotic Lactobacillus and Bifidobacterium strains colonize the gut
only transiently and disappear from feces within days or weeks after the administration [3]. However,
a recent study showed that long-term persistence of an administered Bifidobacterium longum strain for
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up to six months is possible in a subset of individuals and that the colonization was more efficient when
endogenous B. longum strains were underrepresented [4]. Thus, the engraftment was influenced by the
endogenous microbiota and a niche opportunity in the gut ecosystem. In this respect, the colonization
of probiotics in infants with undeveloped microbiota and weaker colonization resistance may be more
long-term, possibly even for a lifetime, and the health effects may also be more profound, which
emphasizes the importance of appropriate strain selection.
The traditional selection criteria for probiotics take into account both safety and functionality as
well as technological usefulness [2]. In addition to the selection criteria summarized in [2], probiotic
products may need to be tailored for the specific target subpopulation of interest. A recently reported
study used such an approach, where the authors first carried out a pilot study and selected the probiotic
strain to be used by its ability to effectively colonize in the target population, and then demonstrated in
a large clinical trial (n = 4556) that a synbiotic mix containing the selected strain Lactobacillus plantarum
and prebiotic fructooligosaccharides reduced neonatal sepsis and death among infants in rural India
by 40 % [5].
While probiotics offer an attractive preventive or adjunct therapy for various diseases [2], the most
striking evidence of the possibilities to treat diseases by microbiota modulation has been obtained by
fecal microbiota transplantation (FMT) treatment of recurrent Clostridioides difficile (rCDI) infection,
with efficacy rates even exceeding 90% [6]. In rCDI patients, microbiota modulation by FMT has been
shown to restore the disturbed ecosystem and the effect is long-term [7,8]. Thereby, FMT is currently
considered as a possible treatment option for several diseases that are associated with microbiota
dysbiosis [6]. Gut microbiota research and FMT studies have underlined the importance of commensal
species in maintaining gut health and provided leads for the development of next-generation probiotics
and live biotherapeutics based on core species, i.e., commensals that are underrepresented in microbiota
dysbiosis [9,10]. On the other hand, prebiotics have great potential in modifying the residing gut
microbiota and stimulating beneficial bacteria therein, and their potential should be studied further [2].
For example, the consumption of dietary fiber or prebiotics such as inulin may increase the abundance
of Faecalibacterium prausnitzii [11], which is an abundant anti-inflammatory gut species and is found
to be depleted in individuals with inflammatory bowel disease [12]. In general, prebiotic-based
nutritional approaches seem very attractive in targeting extremely oxygen-sensitive commensals
such as F. prausnitzii, whose utilization as a next-generation probiotic could prove technologically
very challenging.
Adherence to the intestinal epithelium and immunomodulation have been considered as desired
probiotic properties [2], and screening for such properties may prove useful also for the strain selection of
next-generation probiotics. Further selection properties may include also the production of extracellular
vesicles (EV), which due to their small size can reach the gut epithelium in places where the mucus
layer is firm and impermeable to bacteria and enable bacteria–host crosstalk without direct contact.
Both Gram-negative and Gram-positive bacteria, including several Lactobacillus and Bifidobacterium
strains, have been found to produce EVs, which can carry different components and functional cargos
depending on the organism and growth conditions [13]. Importantly, many promising next-generation
probiotics candidates, such as Bacteroides spp. and Akkermansia muciniphila, are known to produce
EVs, which may contribute to their functionality in alleviating inflammation and reinforcing epithelial
integrity [10,13,14]. EVs could possibly be used as biotherapeutic agents to avoid the risks associated
with the use of live bacteria in high-risk individuals, e.g., those with compromised immunity.
The knowledge on microbes with potential health benefits has extended dramatically in the
past decade. Gut microbiota is a source of novel probiotics and prebiotic innovations, and with the
introduction of next-generation probiotics, we are entering a new era of probiotic research. In the
future, we are likely to see probiotics that have been developed to target specific health issues and
needs. In this regard, a proof-of-concept study with A. muciniphila supplementation showed an
improvement of metabolic parameters in overweight and obese individuals [15]. The translation of gut
microbiota research results to human health has begun, but many of these are still at the very early
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stage of investigation, and the lessons learned from traditional probiotics can help the development of
next-generation probiotics.
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